EMN 29 - Seli-Pom-Dex Vs Elo-Pom-Dex - Multiple Myeloma Clinical Trials
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study | Blood Cancer Journal
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial - The Lancet Haematology
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma | NEJM
Elotuzumab Plus Pomalidomide and Dexamethasone for R/R Multiple Myeloma - Cancer Therapy Advisor
Continuous Elotuzumab, Pomalidomide and Dexamethasone Maintenance Following Second Autologous Transplant for Multiple Myeloma: Results of a Prospective, Phase 2 Multicenter Trial - Transplantation and Cellular Therapy, Official Publication of the ...
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials | Haematologica
Pomalidomide, Dexamethasone, & Elotuzumab Combo Trial
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study | Blood Cancer Journal
Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab - Hermann Einsele, Martin Schreder, 2016
ELOQUENT-3: A New Elotuzumab-Based Triplet Combination in Previously Treated Myeloma
Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial | Journal of Clinical Oncology
Progression-free survival with elotuzumab/pomalidomide/dexamethasone... | Download Scientific Diagram
EHA Library - The official digital education library of European Hematology Association (EHA)
Empliciti (elotuzumab) for the Treatment of Multiple Myeloma, USA
Empliciti; INN-elotuzumab
Characterization of Synergistic Selinexor Combinations of Dexamethasone, Pomalidomide, Elotuzumab and Daratumumab in Primary MM Samples Ex Vivo - ScienceDirect
Progression-free survival with elotuzumab/pomalidomide/dexamethasone... | Download Scientific Diagram
Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone - ScienceDirect
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma | NEJM
When and How to Treat Relapsed Multiple Myeloma | American Society of Clinical Oncology Educational Book
Elotuzumab
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial - The Lancet Oncology
Population pharmacokinetic and exposure–response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma | Cancer Chemotherapy and Pharmacology
Clinical Trial: For Patients Resistant to Lenalidomide, the Antibody Elotuzumab With the Newer Pomalidomide and Dex for Relapsed/Refractory Myeloma - HealthTree for Myeloma
